LncRNA FOXD3-AS1 Promotes Tumorigenesis of Glioma via Targeting miR-128-3p/SZRD1 Axis

Li, Zhang; Li, Ming; Xia, Pengcheng; Wang, Lili; Lu, Zhiming

doi:10.2147/cmar.s324920

Cited by 3 publications

(5 citation statements)

References 35 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The creation of GSC niches at the tumor border, as reported by Hide et al [ 47 ] emphasizes the dynamic interplay between oligodendrocyte progenitor cells, macrophages/microglia, and the GSC microenvironment. This aligns with the findings of Li et al [ 42 ] where PI3Kγ inhibition suppresses microglia/TAM accumulation in the glioblastoma microenvironment. The intercellular crosstalk between GSCs and immune components suggests a complex landscape that contributes to therapy resistance.…”

Section: Discussionsupporting

confidence: 92%

“…In parallel, Wu et al [ 44 ] demonstrate the role of lnc-TALC in promoting O6-methylguanine-DNA methyltransferase expression, a key contributor to TMZ resistance[ 17 ]. These findings resonate with the growing body of evidence highlighting the regulatory role of lncRNAs in glioma progression[ 42 ].…”

Section: Discussionsupporting

confidence: 79%

“…The study by Alhaddad et al [ 40 ] delves into the role of autophagy induction in promoting M2-like macrophage polarization, thereby contributing to radioresistance[ 41 ]. This contrasts with Li et al [ 42 ] where PI3Kγ inhibition suppresses microglia/TAM accumulation in the glioma microenvironment by inhibiting autophagy, ultimately promoting an exceptional response to TMZ[ 2 ]. The dual role of autophagy in GSC-mediated resistance mechanisms highlights the need for a nuanced understanding of context-dependent responses to therapeutic interventions[ 4 ].…”

Section: Discussionmentioning

confidence: 74%

See 2 more Smart Citations

Role of glioma stem cells in promoting tumor chemo- and radioresistance: A systematic review of potential targeted treatments

Agosti,

Zeppieri,

Ghidoni

et al. 2024

World J Stem Cells

View full text Add to dashboard Cite

BACKGROUND Gliomas pose a significant challenge to effective treatment despite advancements in chemotherapy and radiotherapy. Glioma stem cells (GSCs), a subset within tumors, contribute to resistance, tumor heterogeneity, and plasticity. Recent studies reveal GSCs’ role in therapeutic resistance, driven by DNA repair mechanisms and dynamic transitions between cellular states. Resistance mechanisms can involve different cellular pathways, most of which have been recently reported in the literature. Despite progress, targeted therapeutic approaches lack consensus due to GSCs’ high plasticity. AIM To analyze targeted therapies against GSC-mediated resistance to radio- and chemotherapy in gliomas, focusing on underlying mechanisms. METHODS A systematic search was conducted across major medical databases (PubMed, Embase, and Cochrane Library) up to September 30, 2023. The search strategy utilized relevant Medical Subject Heading terms and keywords related to including “glioma stem cells”, “radiotherapy”, “chemotherapy”, “resistance”, and “targeted therapies”. Studies included in this review were publications focusing on targeted therapies against the molecular mechanism of GSC-mediated resistance to radiotherapy resistance (RTR). RESULTS In a comprehensive review of 66 studies on stem cell therapies for SCI, 452 papers were initially identified, with 203 chosen for full-text analysis. Among them, 201 were deemed eligible after excluding 168 for various reasons. The temporal breakdown of studies illustrates this trend: 2005-2010 (33.3%), 2011-2015 (36.4%), and 2016-2022 (30.3%). Key GSC models, particularly U87 (33.3%), U251 (15.2%), and T98G (15.2%), emerge as significant in research, reflecting their representativeness of glioma characteristics. Pathway analysis indicates a focus on phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (mTOR) (27.3%) and Notch (12.1%) pathways, suggesting their crucial roles in resistance development. Targeted molecules with mTOR (18.2%), CHK1/2 (15.2%), and ATP binding cassette G2 (12.1%) as frequent targets underscore their importance in overcoming GSC-mediated resistance. Various therapeutic agents, notably RNA inhibitor/short hairpin RNA (27.3%), inhibitors (e.g., LY294002, NVP-BEZ235) (24.2%), and monoclonal antibodies (e.g., cetuximab) (9.1%), demonstrate versatility in targeted therapies. among 20 studies (60.6%), the most common effect on the chemotherapy resistance response is a reduction in temozolomide resistance (51.5%), followed by reductions in carmustine resistance (9.1%) and doxorubicin resistance (3.0%), while resistance to RTR is reduced in 42.4% of studies. CONCLUSION GSCs play a complex role in mediating radioresistance and chemoresistance, emphasizing the necessity for precision therapies that consider the heterogeneity within the GSC population and the dynamic tumor microenvironment to enhance outcomes for glioblastoma patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

Role of glioma stem cells in promoting tumor chemo- and radioresistance: A systematic review of potential targeted treatments

Agosti,

Zeppieri,

Ghidoni

et al. 2024

World J Stem Cells

View full text Add to dashboard Cite

show abstract

“…In our study, we construct succinylation-related lncRNAs, including FOXD3-AS1, ANK3-DT, EIF3J-DT, MIR210HG, MAFA-AS1 and AC024581.1. Combined with our results, the lncRNA FOXD3-AS1 con rmed overexpressed in glioma, colon cancer and lung cancer [17][18][19][20]. Besides, a series study that ferroptosis and autophagy related lncRNA model constructed risk signature for CC prognosis containing EIF3J-DT [21,22].…”

Section: Disscussionsupporting

confidence: 66%

Succinylation-Associated LncRNA Signature as the Prognosis of Colon Cancer Identified by an Integrative Bioinformatics Analysis

Zhang

Shen

et al. 2022

Preprint

View full text Add to dashboard Cite

Though treatment techniques and strategies for colon cancer (CC) enhanced, the 5-year survival rate has not been significantly improved. Succinylation and long noncoding RNAs (lncRNAs) are uncertain for the prognostic value in the CC patients. We applied to analyze and obtain succinylation-related lncRNA by coexpression in CC. A novel succinylation-related lncRNA model was constructed by univariate and lasso regression analysis and established principal component analysis (PCA), functional enrichment annotation, tumor immune environment, drug sensitivity and nomogram to verify the model, respectively. Six succinylation-related lncRNA in CC were finally confirmed and distinguish the survival status in our model which was statistically significant differ in training set, testing set, and entire set. The prognosis value with this model associated with age, gender, M0 stage, N2 stage, T3+T4 stage and Stage III+IV. The high-risk group showed a higher mutation rate than the low-risk group. We constructed a model predict overall survival for 1-, 3-, and 5-year with AUCs of 0.694, 0.729, and 0.802. Cisplatin and Temozolomide compounds possess sensitivity in the high-risk group. Our study provided novel insights into the value of the succinylation related lncRNA signature as a predictor of prognosis, which possess high clinical application value in the future.

show abstract

“…Several studies have investigated the role of FOXD3-AS1 in cancer. Here, we investigated the role of the immune system in the expression of FOXD3-AS1 in glioma ( Wu et al, 2019 ; Sun et al, 2020 ; Li et al, 2021b ; Li et al, 2021a ). The relationship between FOXD3-AS1 and immune cells was analyzed in TCGA (The Cancer Genome Atlas) database using CIBERSORT and TIMER.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value and immune-infiltration pattern of FOXD3-AS1 in patients with glioma

et al. 2023

View full text Add to dashboard Cite

Gliomas are difficult-to-treat brain tumors due to their aggressive nature, rapid proliferation, and high invasiveness (Zhang et al., J Cell Biochem, 2019, 120 (9), 15106–15118; Ge et al., Int J Biochem Cell Biol, 2021, 139, 106054). FOXD3-AS1 has been identified as an emerging potential target for tumor prediction and treatment in many studies (Qin et al., Front Oncol, 2021, 11, 688027). However, the utility of FOXD3-AS1 has not been reported in glioma patients (Li et al., Cancer Manag Res, 2021, 13, 9037–9048). The differential profiles of FOXD3-AS1 in TCGA–GBMLGG database were analyzed across clinical subgroups. The analysis of overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) revealed that a high level of FOXD3-AS1 was associated with a poor prognosis and survival outcome. Based on the Cox regression analysis, FOXD3-AS1 was found to be a high-risk factor for glioma that affects prognosis outcomes independently. More importantly, because oxidative stress is closely linked to glioma prognosis, we focused on the potential mechanisms of six oxidative stress co-expressed genes with FOXD3-AS1. In addition, the predictive value of FOXD3-AS1 was determined for each clinical subgroup status. The ROC curve results showed that FOXD3-AS1 had a good predictive performance. A stratified clinicopathological subgroup analysis revealed that high expression of FOXD3-AS1 is associated with a poor prognosis. This also indicates a link between FOXD3-AS1 and tumorigenesis and prognosis, which has potential application value. Furthermore, the immune cell infiltration of FOXD3-AS1 and the signal marker correlation suggested that immune cell infiltration differed significantly between immune cell subsets. To the best of our knowledge, this is the first report to investigate FOXD3-AS1 in glioma and how it may modulate GBM and LGG immune microenvironments. Furthermore, FOXD3-AS1 was detected in tumor and paraneoplastic tissues using RT–qPCR. Transwell analysis verified the migration and invasion of the FOXD3-AS1 knockout group in vitro to a certain extent. In conclusion, FOXD3-AS1 can be used as a prognostic indicator for GBM and LGG, and it is closely related to immune infiltration and response to oxidative stress, which may contribute to the advancement of glioma immunotherapy research.

show abstract

LncRNA FOXD3-AS1 Promotes Tumorigenesis of Glioma via Targeting miR-128-3p/SZRD1 Axis

Cited by 3 publications

References 35 publications

Role of glioma stem cells in promoting tumor chemo- and radioresistance: A systematic review of potential targeted treatments

Role of glioma stem cells in promoting tumor chemo- and radioresistance: A systematic review of potential targeted treatments

Succinylation-Associated LncRNA Signature as the Prognosis of Colon Cancer Identified by an Integrative Bioinformatics Analysis

Prognostic value and immune-infiltration pattern of FOXD3-AS1 in patients with glioma

Contact Info

Product

Resources

About